SCHEMBL23978561

SCHEMBL23978561

CC(C)N(C)c1ncc2ccccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 5/20 0.46
▸ NCF1 P14598 1/20 0.40
▸ RPS6KB1 P23443 1/20 0.39
▸ HTR3A P46098 1/20 0.39
▸ HRH4 Q9H3N8 1/20 0.39
▸ PCSK9 Q8NBP7 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GPR3 P46089 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ NUDT1 P36639 1/20 0.35
▸ CYP2A6 P11509 1/20 0.34
▸ TLR8 Q9NR97 2/20 0.34
▸ BRD9 Q9H8M2 1/20 0.34
▸ IRAK4 Q9NWZ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26488447 0.88 CYP1A2 (0.43) CYP1A2NCF1RPS6KB1HTR3AHRH4
SCHEMBL23773568 0.85 CYP1A2 (0.41) CYP1A2NCF1RPS6KB1HTR3AHRH4
SCHEMBL12003727 0.84 CYP1A2 (0.56) CYP1A2NCF1HTR3AHRH4KDM4E
SCHEMBL31391395 0.84 CYP1A2 (0.56) CYP1A2NCF1HTR3AHRH4KDM4E
SCHEMBL17061539 0.79 CYP1A2 (0.47) CYP1A2NCF1HTR3AHRH4KDM4E
SCHEMBL3337226 0.79 CYP1A2 (0.47) CYP1A2NCF1HTR3AHRH4KDM4E
SCHEMBL23978672 0.76 CYP1A2 (0.45) CYP1A2NCF1RPS6KB1HTR3AHRH4
Hydrochloric Acid SCHEMBL10583130 0.75 CYP1A2 (0.47) CYP1A2NCF1KDM4EEGFR
SCHEMBL12890436 0.73 CYP1A2 (0.52) CYP1A2HTR3AKDM4EALDH1A1GLA
SCHEMBL4547884 0.71 CYP1A2 (0.43) CYP1A2NCF1HTR3AHRH4PCSK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 — — US disclosed
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 — — US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 — — US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 — — US disclosed
US-20220411366-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-29 — — US disclosed
WO-2021222789-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof ITGB1, ITGB2, ITGA2 CYP1A2 2939/4885NCF1 617/4885RPS6KB1 836/4885
US-20230135152-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIP5K1C CYP1A2 4578/4885NCF1 1561/4885RPS6KB1 378/4885
US-20220411366-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF ITGB1, ITGB2, ITGA2 CYP1A2 2939/4885NCF1 617/4885RPS6KB1 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback